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Abstract   
 Fast and easy screening procedures are essential in any forensic toxicology 
laboratory to differentiate negative samples from presumptive positive cases. 
Immunoassay techniques, such as enzyme multiplied immunoassay technique (EMIT), 
are routinely employed as screening procedures. However, these techniques lack 
specificity (only differentiate group of drugs and not individual compounds) and it is 
difficult to add new compounds to the panel. Direct analysis of dried urine spots (DUS) 
by mass spectrometry (MS) offers a novel strategy to overcome these issues. DUS offer 
an improved storage alternative for biological samples, reducing costs and space 
requirements. In this work, an original method to screen for 15 common drugs of abuse in 
dried urine spots is described. The drug groups included opioids, prescription opioids, 
amphetamines and cocaine. Using a thin-layer chromatography-mass spectrometry (TLC-
MS) interface, DUS samples were directly sampled and mass spectral data were 
analyzed. The method allows for analysis of DUS samples in less than five minutes and 
only 20 µL of sample is required for analysis. The method was validated according to 
SWGTOX guidelines, including limit of detection (LOD) and interference studies. The 
LOD ranged from 100 to 1,000 ng/mL, depending on the compound. The performance of 
the DUS screening method was compared to EMIT. The DUS method was more specific 
than the immunoassay screening but less sensitive than EMIT for certain analytes 
including morphine, hydrocodone, codeine, and 6-monoacetylmorphine. While this DUS 
screening method is rapid and easy to perform, urinary matrix components can possibly 







 Dried blood spot (DBS) sampling is a well-established technique which has been 
used for screening of neonatal metabolic disorders for decades. Recently, there has been 
increased interest in the use of DBS as an alternative to conventional venous blood 
sampling, and also as a storage procedure of other types of biological matrices, dried 
matrix spot (DMS), to support pharmacokinetic and toxicokinetic studies in therapeutic 
drug monitoring (TDM) and for the detection of drugs of abuse in forensic settings 
(Antunes, Charao, & Linden, 2016; Oliveira, Henion, & Wickremsinhe, 2014; Stove, 
Ingels, De Kesel, & Lambert, 2012). DBS sampling has many advantages over traditional 
blood collection, which include a less invasive sampling technique and reduced blood 
volume requirements. In addition, DBS and DMS techniques offer a low biohazard risk, 
reductions in sample processing, storage and transportation costs (Sadones, Capiau, De 
Kesel, Lambert, & Stove, 2014), and improved stability for some drugs and metabolites 
(Abu-Rabie & Spooner, 2009; Oliveira et al., 2014).  
DMS are gaining popularity in toxicology laboratories and have been employed 
as alternative sample collection and storage procedure for confirmatory analysis and for 
screening procedures. DMS have been employed in blood (Berm et al., 2014; H. Lee et 
al., 2015), urine (Y. Lee, Lai, & Sadrzadeh, 2013; Otero-Fernandez et al., 2013), plasma 
and other matrices (Ayre, Chaudhari, Jagdale, & Agrawal, 2018). The typical DMS work 
flow in a confirmatory analysis involves punching a disk from the center of the spot, 
transferring the disk to a tube, and extracting the sample with a solvent containing an 
internal standard. Furthermore, additional sample preparation and cleanup such as liquid-






chromatography tandem mass spectrometry (LC-MSMS). Although DMS offers several 
advantages as highlighted above, the DMS confirmatory analysis may be time consuming 
and tedious, especially when a large number of samples need to be prepared for analysis 
(Oliveira et al., 2014).  
A suitable direct analysis technique for DMS samples without sample pre-
treatment and extraction could simplify sample preparation and provide significant cost 
and time savings. Also, the elimination of the need for the sample separation by liquid 
chromatography (LC) would simplify the procedure (Abu-Rabie & Spooner, 2009). 
Although the lack of sample pre-treatment, extraction and chromatographic separation 
may decrease the sensitivity and specificity of the technique as confirmatory tool, it may 
be used as screening procedure. Toxicology laboratories routinely employ immunoassays 
(EMIT, ELISA), gas-chromatography mass spectrometry (GC-MS), or HPLC with diode-
array detection (DAD) to perform drug screening tests. Each of these techniques have 
limitations including lack of specificity and difficulty of incorporating new targets 
(immunoassays), or labor-intensive sample preparation and instrument maintenance (GC-
MS and HPLC-DAD), thus there is a need to develop novel techniques that provide a 
simpler, faster, sensitive and more cost-effective screening method that would enable 
toxicology labs to operate more efficiently (Gaugler, Rykl, Grill, & Cebolla, 2018; Jett, 
2017). 
Several surface-sampling probes exist that could be used for the direct analysis 
with MS detection. These probes could enable the direct analysis of DMS without sample 
preparation, extraction, and chromatographic separation. Two examples of these probes 






applied to extraction of analytes from the surfaces of hard and nonporous materials like 
glass or metal, and the sealing surface sampling probe (SSSP), used on porous surfaces, 
including most filter papers, such as DBS filter paper (Deglon, Thomas, Mangin, & 
Staub, 2012). Luftmann (2004) described the development of a device which allowed for 
the direct sampling of thin layer chromatography (TLC) plates to an electrospray 
ionization (ESI) mass spectrometer and an automated TLC-MS interface (Luftmann, 
2004; Luftmann, Aranda, & Morlock, 2007). This type of probe was a sealing surface 
sampling probe (SSSP). Van Berkel et al (2002, 2009) also described the development of 
a combined surface sampling probe/electrospray emitter to directly sample TLC plates by 
ESI mass spectrometry. His group developed the liquid microjunction surface sampling 
probe (LMJ-SSP), which was shown to be capable of direct mass spectrometric analysis 
of drugs and metabolites in DBS samples and whole mouse thin tissue sections (Van 
Berkel & Kertesz, 2009; Van Berkel, Sanchez, & Quirke, 2002) 
Other examples of direct sampling and ionization techniques include Direct 
Analysis in Real Time (DART) and paper spray ionization (PSI). Beck, et al (2016) 
developed a method to screen for and confirm methadone in untreated urine specimens 
using DART coupled with both time-of-flight and triple quadrupole linear ion trap (Q-
TRAP) mass spectrometers. DART-MS allows for ambient ionization of samples and 
does not rely on chromatography for separation. It relies on the mass spectrometer for 
separation, which allows for data acquisition in real time (Beck, Carter, Shonsey, & 
Graves, 2016). Jeong, et al. (2016) developed a rapid and direct paper spray ionization-
mass spectrometry (PSI-MS) method for quantitative analysis of ephedrine, 






ionization generates ions by applying high voltage to a triangular piece of filter paper 
wetted with solvent. PSI-MS allows for direct analysis of a sample without complex 
preparation and chromatographic separation, which allows for reduced sample 
preparation and analytical times. Their method employed high-resolution mass 
spectrometry (Orbitrap) with a triple-quadrupole mass spectrometer which allowed for 
confirmation of the ephedrines tested (Jeong et al., 2016).  
Mass spectrometry has become essential in toxicological analysis.  Conventional 
laboratory scale mass spectrometers are combined with gas or liquid chromatography, 
making them very bulky. Thus, there is a desire to miniaturize MS systems so that the 
systems can fit on a bench-top or be portable so that they can be used in the field for 
seized substance identification, food and cosmetics analysis, and point-of-care analysis 
(Bu, Regalado, Hamilton, & Welch, 2016; Eikel, Prosser, & Henion, 2015; Lawton et al., 
2017; Ma et al., 2015; Ma et al., 2016; Ma & Ouyang, 2016). Analysis by miniature and 
compact mass spectrometers may play a unique role in bioanalysis in that it allows users 
to obtain MS results at their own benches without a need to send samples to analytical 
laboratories. One such compact mass spectrometer (CMS) system is the Advion 
Expression CMS. The Advion system is a compact version of a single quadrupole MS 
instrument which can be coupled to the PlateExpress TLC plate reader, which allows for 
rapid and direct ESI-MS analysis of spots on a TLC plate (Bu, Yang, Gong, & Welch, 
2014). If the TLC-CMS interface could be applied to DMS cards, it could be possible to 
develop a direct analysis of DMS samples to screen for drugs of abuse. 
The goal of our project was to develop and validate a new screening method 






a portable single quadrupole mass spectrometer. The method allowed the screening of 15 
drugs and metabolites, including opioids, amphetamines, and cocaine. DUS were directly 
extracted and analyzed, eliminating the punching and subsequent extraction steps that are 
involved in the manual work flow for DMS analysis. This novel methodology in direct 
sampling and ionization has the potential to provide significant time and cost savings 
while greatly simplifying analysis in the toxicology laboratory.   
Methods and Materials 
1. Reagents and Materials 
 TLC plates, Analtech TLC UniplatesTM high performance silica gel thin layer 
chromatography plates (150 micron, 10x20 cm), and WhatmanTM 903 protein saver cards 
were purchased from Fisher Scientific (Hampton, NH). Morphine, 6-
monoacetylmorphine (6-AM), codeine, hydrocodone, oxycodone, fentanyl, norfentanyl, 
methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), cocaine, 
benzoylecgonine, amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine 
(MDA), and 3,4-methylenedioxymethamphetamine (MDMA) 1 mL ampoule standards in 
methanol at 1 mg/mL were purchased from Cerilliant (Round Rock, TX). Synthetic urine 
was purchased from Ricca Chemical Company (Pocomoke City, MD). Authentic urine 
samples were provided by volunteers in the laboratory. The amphetamine, cocaine, 
methadone, and opiate EMIT II Assay kits were purchased from Siemens (Munich, 
Germany). 






 To determine the limit of detection (LOD) or cut-off for each drug in methanol, 
synthetic urine, and authentic urine, samples were prepared at 100, 250, 500, 1,000, and 
10,000 ng/mL. The synthetic and authentic urine samples were prepared by spiking 200 
µL of the samples to with the appropriate amount of 100,000, 10,000 or 1,000 ng/mL 
standard needed  to reach the desired concentration.  
3. Blind urine sample preparation 
 To test the performance of the screening test, 5 urine samples were fortified with 
different drugs (methamphetamine, amphetamine, morphine, hydrocodone, 
benzoylecgonine, MDMA, methadone, EDDP, or oxycodone) at 500 ng/mL. These 
samples were prepared by another member of the laboratory and were analyzed by the 
screening method and by EMIT.  
4. TLC spot preparation 
 The methanolic drug standards were diluted to 100,000 ng/mL, and these 
solutions were spotted onto the TLC plates using micro capillary tubes. The spot was 
circled with pencil and allowed to dry for approximately two minutes prior to analysis.  
5. DMS preparation 
 For the methanolic drug samples, 20 µL of sample was dispensed into the center 
of the spot on the card and allowed to dry for 10 min at room temperature before analysis. 
For the synthetic and authentic urine samples, 20 µL of sample was dispensed into the 
center of the spot on the card and were allowed to dry overnight at room temperature 






To determine cut-off intensities and conduct interference studies, the spot was cut 
from the card after drying, and it was placed on a clean microscope slide for analysis to 
avoid cross-contamination between spots. 
6. Instrumentation 
 The instrument employed was a PlateExpress TLC plate reader coupled to the 
Expression compact mass spectrometer (CMS), both from Advion (Ithaca, NY) (Figure 
1). The Plate Express is a device that provides a simple, semi-automated means of 
obtaining mass spectra directly from TLC plates by direct solvent extraction of 
compounds. The plate reader has an elution head which lowers itself onto the spot of 
interest, presses firmly into the plate to form a seal, then flows solvent over the spot to 
extract the sample and sends this solution to the mass spectrometer (Advion, 2015) 
(Figure 2). The solvent that we employed was 0.1% formic acid in acetonitrile at a flow 
rate of 2.5 mL/min. 
The Advion Expression CMS is a single quadrupole MS. We employed the 
electrospray ionization (ESI) source in positive mode. Data was acquired in scan mode, 
with a mass range from 88 to 500 m/z. The ESI parameters were as follows: capillary 
temperature 200 °C, capillary voltage 150.0 V, source voltage offset 20.0 V, source 
voltage span 30.0 V, ESI source gas temperature 200 °C, and ESI voltage 3,500 V. The 
MS parameters used were as follows: extraction electrode 9 V, hexapole bias 8 V, 
hexapole RF offset 0, hexapole RF span 140, ion energy offset -1.2, ion energy span 0, 







Figure 1. (A). TLC-MS system used in this work. On the left is the Advion CMS and on 
the right is the PlateExpress TLC plate reader. (B). Close-up view of PlateExpress 
extraction device. (Advion, 2015). 
 
Figure 2. Schematic view of PlateExpress elution head. The blue line shows extraction 
solvent flowing down to the sample spot of interest. The green line shows the solution 






EMIT screening was performed using a VivaTM Drug Testing System from 
Siemens (Munich, Germany). Five hundred µL of each authentic urine sample was used 
to screen for amphetamines, cocaine, methadone, and opiates. For amphetamine 
screening, a 1,000 ng/mL cut-off concentration was used. For cocaine, methadone, and 
opiate screening a 300 ng/mL cut-off concentration was used.  
7. Validation of DUS screening method 
 The screening assay was validated according to the SWGTOX guidelines 
(Scientific Working Group for Forensic Toxicology, 2013). To validate the screening 
method, we evaluated the limit of detection LOD or cut-off of each analyte of interest in 
methanol, synthetic urine, and authentic urine, and conducted interference studies. In 
order to determine the LODs for each drug in a particular matrix, DMS spots were 
prepared at 10,000, 1,000, 750, 500, 250, and 100 ng/mL. Additional samples were 
prepared at 200 ng/mL for cocaine and benzoylecgonine. The lowest concentration at 
which the compound could be repeatedly and reliably detected was designated as the 
LOD. In order to assess the possibility of endogenous interferences, blank urine samples, 
which had not been fortified with any drug, were tested. Any peaks detected in the blank 
with a mass-to-charge ratio identical to one of the analytes of interest was designated as 
endogenous interference. Additional compounds that could possibly account for any 
observed interferences (endogenous and exogenous interferences), due to their similar 
molecular weight to the target analytes, were identified by searching the Human 







Results and Discussion 
1. TLC Analysis 
 Prior to analysis of drugs extracted from DMS cards, each drug standard (100,000 
ng/mL) was spotted on and extracted from a TLC plate. The mass spectrum of each pure 
drug was obtained in order to determine the target ion m/z of interest (Table 1).  
Table 1. Mass spectral data of the analytes of interest extracted from TLC plates. No 
fragmentation was observed for analytes with no information in the product ion column 
Drug Molecular Weight (g/mol) 




Morphine 285.3 286.1 - 
6-AM 327.3 328.1 - 
Oxycodone 315.3 316.2 - 
Hydrocodone 299.3 300.2 - 
Codeine 299.3 300.2 - 
Fentanyl 336.4 337.3 - 
Norfentanyl 232.3 233.1 - 
Methadone 309.4 310.2 265.0 
EDDP 277.4 278.1 - 
Amphetamine 135.2 136.1 119.1, 91.1 
Methamphetamine 149.2 150.0 119.1, 91.1 
MDMA 193.2 194.1 163.0 
MDA 179.2 180.0 163.0 
Cocaine 303.3 304.2 182.1 
Benzoylecgonine 289.3 290.1 168.0 
 
  By extracting the drug standards from TLC plates, we were able to analyze the 
mass spectral data for each analyte, including the parent ion and determine if any 
fragmentation occurred. This information was helpful in determining which ions to 
monitor in the DUS samples and for establishing what criteria should be met in order to 
determine if a sample was positive. Morphine, 6-AM, oxycodone, hydrocodone, codeine, 
fentanyl, norfentanyl, and EDDP did not undergo any fragmentation. Therefore, we could 






Methadone, MDMA, MDA, cocaine, and benzoylecgonine each displayed one precursor 
and one fragment ion. The presence of a characteristic fragment ion improves the 
specificity of the analysis, because we can rely on the presence and intensity of both ions 
when making conclusions. Amphetamine and methamphetamine displayed a precursor 
and two fragment ions (Table 1).  
2. Determination of Limit of Detection on DMS cards 
 To determine if the Whatman 903 card had any effect on the mass spectral data, 
we applied 20 µL of each drug standard at 100,000 ng/mL to the center of the spot and 
directly analyzed the spot using the TLC-CMS interface. All parent and fragment ions 
observed when using the TLC plate were observed when extracting the methanolic 
standards from the card. We determined the LOD for each methanolic drug standard on 
the DMS card (Table 2). This gave us an idea of the instrumental LOD and informed us 
of what concentrations to proceed with when determining the LOD in synthetic and 
authentic urine. For example, the LOD of the oxycodone, hydrocodone, and codeine 
standards on the DBS cards were all 500 ng/mL. Therefore, the lowest concentration 
synthetic and authentic urine samples prepared for these drugs were 500 ng/mL. These 
results were mostly in agreement with LOD data published by the manufacturer 
(Orlowicz et al., 2019). 
Table 2. Mass spectral and LOD data for methanolic drug standards extracted from the 
Whatman 903 cards. 





Peak Intensity at 
LOD 
Morphine 286.1 - 100 1.4E6 
6-AM 328.1 - 100 6.7E5 
Oxycodone 316.2 - 500 1.3E5 






Codeine 300.2 - 500 2.4E5 
Fentanyl 337.3 - 100 2.9E5 
Norfentanyl 233.1 - 100 2.4E5 
Methadone 310.2 265.0 100 1.4E6 
EDDP 278.1 - 100 1.2E6 
Amphetamine 136.1 119.1, 91.1 100 6.4E5 
Methamphetamine 150.0 119.1, 91.1 100 3.3E5 
MDMA 194.1 163.0 100 5.8E5 
MDA 180.0 163.0 100 1.6E5 
Cocaine 304.2 182.1 100 6.1E5 
Benzoylecgonine 290.1 168.0 100 3.9E5 
 
 After determining the LOD of each drug in methanol, samples were prepared in 
synthetic urine. The mass spectral data and LOD of each drug in synthetic urine is 
summarized in Table 3. In synthetic urine, the LOD for morphine, 6-AM, amphetamine, 
methamphetamine, MDMA, and MDA increased from 100 ng/mL to 250 ng/mL. In 
addition, the 182.1 m/z product ion of cocaine was no longer detectable in synthetic urine. 
Table 3. Mass spectral and LOD data for dried synthetic urine samples. 







Morphine 286.0 - 250 6.6E5 
6-AM 328.1 - 250 1.2E5 
Oxycodone 316.2 - 500 2.0E5 
Hydrocodone 300.2 - 500 2.1E5 
Codeine 300.2 - 500 1.9E5 
Fentanyl 337.3 - 100 4.9E5 
Norfentanyl 233.0 - 100 2.2E5 
Methadone 310.2 265.0 100 5.8E5 
EDDP 278.1 - 100 2.4E5 
Amphetamine 136.1 119.1, 91.1 250 1.8E5 
Methamphetamine 150.1 119.1, 91.1 250 3.2E5 
MDMA 194.1 163.0 250 1.4E5 
MDA 180.0 163.0 250 1.5E5 
Cocaine 304.2  100 4.8E5 







Finally, drug samples were prepared in negative authentic urine samples. To determine 
the LOD , each drug was prepared in three different authentic urine samples and analyzed 
by TLC-CMS. Mass spectral and LOD data is summarized in Table 4. The LOD for 
morphine, 6-AM, amphetamine, methamphetamine, MDMA, and MDA increased from 
250 ng/mL in synthetic urine to 500 ng/mL in authentic urine. The LOD for oxycodone, 
hydrocodone, and codeine increased from 500 ng/mL in synthetic urine to 1,000 ng/mL 
in authentic urine. The LOD for cocaine and benzoylecgonine increased from 100 ng/mL 
in synthetic urine to 200 ng/mL in authentic urine. In addition, the product ions for 
amphetamine and methamphetamine were no longer detectable in authentic urine. Matrix 
components and urinary metabolites may impact the ability to detect the target analyte. 
The significant increase in LOD for these drugs and inability to detect certain ions is 
likely caused by matrix effects due to the complex chemical composition of urine. The 
LOD and fragmentation pattern for each analyte in authentic urine was used to determine 
the cut-off intensity and ions to be monitored when screening unknown samples (Table 
5). 
 Table 4. Mass spectral and LOD data for dried authentic urine samples. 





Peak Intensity at LOD 
(cut-off intensity) 
Morphine 286.1 - 500 1.75E6 
6-AM 328.1 - 500 2.33E5 
Oxycodone 316.2 - 1000 2.20E5 
Hydrocodone 300.2 - 1000 2.39E5 
Codeine 300.2 - 1000 2.19E5 
Fentanyl 337.3 - 100 6.92E5 
Norfentanyl 233.1 - 100 2.84E5 
Methadone 310.2 265.0 100 2.03E6 
EDDP 278.1 - 100 1.32E6 
Amphetamine 136.1 - 500 3.68E5 
Methamphetamine 150.0 - 500 3.63E5 






MDA 180.0 163.0 500 2.38E5 
Cocaine 304.2 - 200 2.10E5 
Benzoylecgonine 290.1 168.0 200 2.41E5 
 
Table 5. Cut-off intensities for each individual drug in authentic urine. 
Drug Ion m/z Concentration (ng/mL) 
Average signal 
intensity 
Morphine 286.1 500 1.75E6 
6-AM 328.2 500 2.33E5 
Oxycodone 316.1 1000 2.20E5 
Hydrocodone 300.2 1000 2.39E5 
Codeine 300.2 1000 2.19E5 
Fentanyl 337.3 100 6.92E5 
Norfentanyl 233.1 100 2.84E5 
Methadone 310.2 100 2.03E6 265.0 100 1.32E6 
EDDP 278.1 100 1.52E6 
Amphetamine 136.1 500 3.68E5 
Methamphetamine 150.1 500 3.63E5 
MDMA 194.1 500 1.18E5 163.1 500 2.63E5 
MDA 180.0 500 2.38E5 163.1 500 7.70E5 
Cocaine 304.2 200 2.10E5 
Benzoylecgonine 290.0 200 2.41E5 168.1 200 1.65E5 
 
3. Interference Studies 
Because this method does not involve sample pre-treatment or chromatographic 
separation, identification relies solely on the mass spectrometer. Urine is a biological 
waste material which may contain metabolic breakdown products from food, drinks, 
drugs, environmental contaminants, endogenous waste products, and bacterial by-
products (Bouatra et al., 2013). Thus, it was important to perform interference studies. 
Interferences are non-targeted analytes, such as matrix components, impurities, other 






(Standard Working Group for Forensic Toxicology, 2013). Interferences to target 
analytes can arise from several different situations: intra-target interferences can arise 
from analytical targets of this method with the same parent ion and/or interferences can 
arise from endogenous or exogenous substances potentially present in the urine samples. 
Ten negative authentic urine samples were analyzed prior to fortification in order 
to assess possible endogenous interferences. These data are summarized in Table 6.  
Table 6. Peak intensity of the ions of interest detected in each negative authentic urine 
samples (n=10). 
Ion 
m/z Negative urine samples 
 1 2 3 4 5 6 7 8 9 10 
136 1.40E5 1.4E5 ND 1.5E5 2.0E5 3.0E5 1.3E5 1.4E5 1.6E5 2.4E5 
150 ND 2.4E5 ND ND 1.3E5 2.2E5 2.5E5 2.7E5 2.0E5 2.8E5 
163 ND 1.9E5 1.6E5 ND 1.8E5 1.8E5 ND 1.7E5 2.4E5 1.7E5 
168 1.8E5 1.7E5 2.3E5 2E5 ND ND ND ND ND 1.2E5 
180 ND ND ND ND ND ND ND ND ND 1.9E5 
194 ND ND ND ND ND ND ND ND ND ND 
233 ND 1.5E5 ND ND 1.5E5 1.9E5 ND ND ND 1.5E5 
265 9.3E5 8.7E5 6.1E5 8.3E5 9.1E5 6.9E5 3.7E5 8E5 5.5E5 7.8E5 
278 3.3E5 ND ND ND ND ND ND ND ND ND 
286 1.7E6 1.7E6 1.2E6 1.9E6 1.3E6 8.9E5 9E5 2.3E6 1.6E6 2.1E6 
290 3.2E5 3E5 2.2E5 2.3E5 1.4E5 ND 1.8E5 3.9E5 2.7E5 3.4E5 
300 1.3E5 ND ND 1.8E5 1.4E5 1.6E5 ND ND ND ND 
304 ND ND ND ND ND ND ND ND ND ND 
310.2 1.5E5 1.2E5 2.8E5 3.9E5 1.6E5 1.8E5 ND ND ND ND 
316.2 1.4E5 ND 1.7E5 1.7E5 1.4E5 1.8E5 ND ND 1.8E5 ND 
328 2.6E5 1.2E5 2.7E5 3E5 1.7E5 2.4E5 ND 3.3E5 3.1E5 ND 
337 ND ND ND ND ND ND ND ND ND ND 
ND-Not detected 
The 136.1 m/z peak for amphetamine was detected in 9 of the 10 blank urine 
samples. The 150.0 m/z peak for methamphetamine was detected in 7 of the 10 blank 
urine samples. The 310.2 m/z peak for methadone was detected in 6 of the 10 blank urine 
samples. The 316.2 m/z peak for oxycodone was detected in 6 of the 10 blank urine 






The 290 and 168 m/z peaks for benzoylecgonine presented a complication. The 290 m/z 
peak was detected in 9 of the 10 blank urine samples and for 5 of these the 168 m/z peak 
was also detected. Therefore, we cannot rely on the fragmentation pattern to distinguish 
between benzoylecgonine and possible interferences, so we had to rely solely on the 
intensity of the peaks to make a determination of positive or negative. In addition, the 
286.0 m/z peak for morphine was detected in all 10 blank urine samples and at very high 
intensities (average signal intensity of 1.56E6). This apparent endogenous interference 
makes accurate detection of morphine by this method very difficult and unreliable. 
Without a more thorough analysis of the chemical composition of each urine 
sample we are unable to determine exactly what these interference compounds are. The 
chemical complexity of urine poses a challenge because other compounds may 
complicate results and lead to false positives. To investigate other exogenous or 
endogenous compounds found in urine that could cause interferences with the developed 
drug screening method, the Human Metabolome Database was searched using the LC-
MS search function (Wishart et al., 2018). The results of the search are summarized in 
Table 7. This list is limited to compounds with a parent ion that shares a m/z with an 
analyte of interest and does not include all possible adducts that could appear. 
Table 7. Possible interferences identified for each target ion using the Human 
Metabolome Database. 









































































































Hydroxylated N-acetyl desmethyl frovatriptan 
Hyoscyamine 












































































To determine the if the presence of other drugs in each class have an effect on the 
signal, four mixtures were prepared and analyzed in ten different authentic urine samples. 
Mixtures 1-10A contained 500 ng/mL of amphetamine, methamphetamine, MDMA, and 
MDA (Table 8). Mixtures 1-10B contained 200 ng/mL of cocaine and benzoylecgonine 
(Table 9). Mixtures 1-10C contained 1,000 ng/mL of morphine, 6-AM, oxycodone, 
hydrocodone, codeine, fentanyl, norfentanyl, methadone, and EDDP (Table 10). Mixtures 






When compared to the individual drugs, the average signal intensity for amphetamine 
and methamphetamine decreased in the mixture. In addition, MDMA and MDA were 
only detected in 5 of the 10 urine samples tested. This indicates that the drugs are likely 
interfering with each other resulting in ion suppression. 
Table 8. Signal intensities for each of the ions monitored for amphetamine, 
methamphetamine, MDMA, and MDA in mixtures 1-10A. 
Drug Ion 1A 2A 3A 4A 5A 6A 7A 8A 9A 10A Average signal 
Amphetamine 136.1 2E5 ND 2E5 1.5E5 2.7E5 1.6E5 1.5E5 2.1E5 1.9E5 2E5 1.92E5 
Methamphetamine 150.1 1.8E5 3.2E5 1.5E5 ND 2.2E5 2.4E5 1.4E5 2.6E5 1.4E5 3.1E5 2.18E5 
MDMA 194.1 1.2E5 ND 8E4 ND ND 1.1E5 1.3E5 ND ND 1.5E5 1.18E5 
MDA 180.0 ND ND 1.4E5 ND ND 1.9E5 2.6E5 2E5 ND 3E5 2.38E5 
MDMA/MDA 163.1 2.1E5 3.2E5 1.4E5 1.9E5 1.8E5 3.3E5 1.6E5 1.9E5 3E5 3.6E5 2.38E5 
ND-Not detected. 
 For mixture B, no significant difference in signal intensity was observed when 
compared to the average signal intensity for cocaine and benzoylecgonine individually. 
Therefore, it does not appear that these two compounds interfere with each other. 
Table 9. Signal intensities for each of the ions monitored for cocaine and 
benzoylecgonine in mixtures 1-10B.  
Drug Ion 1B 2B 3B 4B 5B 6B 7B 8B 9B 10B Average signal 
Cocaine 304.2 ND ND 5E5 2.6E5 3.5E5 1.4E5 ND 3.4E5 3.5E5 2.3E5 3.1E5 
Benzoylecgonine 290.0 ND 2.5E5 7.1E5 4.3E5 ND 2E5 1.7E5 ND ND ND 3.52E5 168.1 1.7E5 1.5E5 2E5 1.9E5 3.5E5 ND 1.7E5 1.5E5 3E5 2E5 1.98E5 
ND-Not detected. 
 Regarding mixture C, the data shows that some of the drugs are affected by the 
presence of other compounds in the mixture. Hydrocodone and codeine both have the 
same parent ion, so they are intra-target interferences and cannot be distinguished by this 
method. Oxycodone was only detected in four out of 10 of the samples, which indicates 






In addition, the average signal intensity of morphine in mixture C was significantly less 
than the average signal intensity of morphine alone. The signal intensities for fentanyl, 
norfentanyl, methadone, and EDDP were also lower than expected at a concentration of 
1,000 ng/mL, indicating that some ion suppression could be occurring.  
Table 10. Signal intensities for each of the ions monitored in mixtures 1-10C. 
Drug Ion 1C 2C 3C 4C 5C 6C 7C 8C 9C 10C Average signal 
Morphine 286.1 3.8E5 7.1E5 3.9E5 6.5E5 1E6 7.4E5 3.2E5 7.5E5 8.7E5 3.6E5 6.17E5 
6-AM 328.2 1.7E5 ND 1.3E5 2.4E5 2.3E5 1.9E5 1.7E5 3.2E5 2.4E5 1.1E5 2E5 
Oxycodone 316.1 1.4E5 ND ND 1.4E5 ND 1.6E5 1.7E5 ND ND ND 1.53E5 
Hydrocodone/Codeine 300.2 1.3E5 ND ND 2.1E5 1.7E5 2.3E5 2.4E5 ND 4.6E5 4E5 2.63E5 
Fentanyl 337.3 3.8E5 2.9E5 6.3E5 8.5E5 3.3E5 1E6 2E5 4E5 1.1E6 8.9E5 6.07E5 
Norfentanyl 233.1 1.8E5 3E5 1.7E5 1.3E5 1.5E5 2.1E5 ND ND 1.9E5 1.4E5 1.84E5 
Methadone 
310.2 1.3E6 7.9E5 2.1E6 3.4E6 1.2E6 2.5E6 6E5 1.5E6 2.2E6 2.1E6 1.77E6 
265.0 9.8E6 6.1E5 9.3E5 1.7E6 1.2E6 1.8E6 4.1E5 1.2E6 1.8E6 1.9E6 1.25E6 
EDDP 278.1 1E6 1E6 1.6E6 2.9E6 1.2E6 3.4E6 4.9E5 1.9E6 3.2E6 2.6E6 1.93E6 
 
 Regarding mixture D, all four compounds displayed a decreased signal intensity 
at 100 ng/mL when analyzed as a mixture. Therefore, these compounds may interfere 
with each other when present in a mixture. 
Table 11. Signal intensities for each of the ions monitored in mixtures 1-10D. 
Drug Ion 1D 2D 3D 4D 5D 6D 7D 8D 9D 10D Average signal 
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 4. Blind testing and EMIT results 
 Five urine samples were prepared for screening with our DUS method and labeled 
cases 1 through 5. The same procedure was followed with the case samples as with the 
other authentic urine samples. Three spots were prepared for each case and the average 
ion intensity was compared to the established cut-off intensity in order to make a 
determination of positive or negative. If the average peak intensity for the unknown case 
sample was above the cut-off intensity, the sample was designated as positive for that 
particular substance. For the compounds that displayed fragmentation, an additional 
requirement for making a determination of positive was that both the parent and product 
ions be detected.  
For Case 1, the results indicated that the sample was positive for amphetamine, 
methamphetamine, and benzoylecgonine (Table 12). For Cases 2 and 3, none of the 
analytes displayed a peak intensity above the cut-off value so they were designated as 
negative for all analytes (Tables 13 and 14).  For Case 4, the results indicated that the 
sample was positive for MDMA (Table 15). For case 5, the results indicated that the 
sample was positive for methadone and EDDP (Table 16). 
Table 12. Results obtained for Case 1. 




Spot 3 Average 
Cut-off 
intensity Result 
Morphine 286.1 2E6 1.3E6 1.0E6 1.43E6 1.75E6 N 
6-monoacetylmorphine 328.2 1.8E5 ND 1.6E5 1.7E5 2.33E5 N 
Oxycodone 316.1 ND ND ND - 2.20E5 N 
Hydrocodone/Codeine 300.2 ND ND ND - 2.19E5 N 
Fentanyl 337.3 ND ND ND - 6.92E5 N 
Norfentanyl 233.1 1.8E5 1.6E5 1.5E5 1.63E5 2.84E5 N 
Methadone 310.2 2.4E5 1.8E5 ND 2.1E5 2.03E6 N 265.0 1.1E6 8.0E5 7.7E5 8.9E5 1.32E6 
EDDP 278.1 ND ND ND - 1.52E6 N 






Methamphetamine 150.1 4.2E5 4.3E5 4.1E5 4.2E5 3.63E5 P 
MDMA 194.1 ND ND ND - 1.18E5 N 
MDA 180.0 ND ND ND - 2.38E5 N 
MDMA/MDA 163.1 2.7E5 2.4E5 2.6E5 2.57E5 2.63E5  
Cocaine 304.2 ND ND ND - 2.10E5 N 
Benzoylecgonine 290.0 3.3E5 2.3E5 2.1E5 2.57E5 2.41E5 P 168.1 2.4E5 2.1E5 1.5E5 2.0E5 1.65E5 
ND-not detected; N-negative; P-positive 
Table 13. Results obtained for Case 2. 




Spot 3 Average 
Cut-off 
intensity Result 
Morphine 286.1 1.1E6 9.2E5 7.7E5 9.3E5 1.75E6 N 
6-monoacetylmorphine 328.2 ND ND ND - 2.33E5 N 
Oxycodone 316.1 ND ND ND - 2.20E5 N 
Hydrocodone/Codeine 300.2 ND ND ND - 2.19E5 N 
Fentanyl 337.3 ND ND ND - 6.92E5 N 
Norfentanyl 233.1 1.4E5 ND ND - 2.84E5 N 
Methadone 310.2 ND ND ND - 2.03E6 N 265.0 5.2E5 3.9E5 3.5E5 4.2E5 1.32E6 
EDDP 278.1 ND ND ND - 1.52E6 N 
Amphetamine 136.1 2.7E5 1.9E5 1.7E5 2.1E5 3.68E5 N 
Methamphetamine 150.1 3.1E5 ND ND - 3.63E5 N 
MDMA 194.1 ND ND 1.5E5 - 1.18E5 N 
MDA 180.0 2.2E5 2.0E5 2.4E5 2.1E5 2.38E5 N 
MDMA/MDA 163.1 2.1E5 ND ND - 2.63E5  
Cocaine 304.2 ND ND ND - 2.10E5 N 
Benzoylecgonine 290.0 2.2E5 1.8E5 1.8E5 1.93E5 2.41E5 N 168.1 1.7E5 ND ND - 1.65E5 
ND-not detected; N-negative 
Table 14. Results obtained for Case 3. 




Spot 3 Average 
Cut-off 
intensity Result 
Morphine 286.1 1.2E6 1.2E6 1.3E6 1.23E6 1.75E6 N 
6-monoacetylmorphine 328.2 ND ND ND - 2.33E5 N 
Oxycodone 316.1 ND ND ND - 2.20E5 N 
Hydrocodone/Codeine 300.2 ND ND ND ND 2.19E5 N 
Fentanyl 337.3 ND ND ND ND 6.92E5 N 
Norfentanyl 233.1 1.3E5 1.3E5 ND 1.3E5 2.84E5 N 
Methadone 310.2 ND ND ND ND 2.03E6 N 265.0 4.7E5 5.8E5 5.2E5 5.23E5 1.32E6 
EDDP 278.1 ND ND ND - 1.52E6 N 
Amphetamine 136.1 3.0E5 3.2E5 2.1E5 2.77E5 3.68E5 N 
Methamphetamine 150.1 3.4E5 2.9E5 1.8E5 2.70E5 3.63E5 N 
MDMA 194.1 ND ND ND - 1.18E5 N 
MDA 180.0 1.6E5 1.6E5 1.6E5 1.6E5 2.38E5 N 
MDMA/MDA 163.1 2.2E5 2.3E5 2.1E5 2.2E5 2.63E5  






Benzoylecgonine 290.0 2.4E5 2.3E5 2.3E5 2.33E5 2.41E5 N 168.1 1.5E5 1.6E5 1.8E5 1.63E5 1.65E5 
ND-not detected; N-negative. 
Table 15. Results obtained for Case 4. 




Spot 3 Average 
Cut-off 
intensity Result 
Morphine 286.1 9.8E5 7.2E5 8.3E5 8.43E5 1.75E6 N 
6-monoacetylmorphine 328.2 ND ND 1.6E5 - 2.33E5 N 
Oxycodone 316.1 ND ND ND - 2.20E5 N 
Hydrocodone/Codeine 300.2 ND ND ND - 2.19E5 N 
Fentanyl 337.3 ND ND ND - 6.92E5 N 
Norfentanyl 233.1 1.3E ND ND - 2.84E5 N 
Methadone 310.2 2.8E5 ND ND - 2.03E6 N 265.0 2.6E5 3.9E5 4.6E5 3.7E5 1.32E6 
EDDP 278.1 3.1E5 ND ND - 1.52E6 N 
Amphetamine 136.1 3.7E5 1.7E5 2.3E5 2.57E5 3.68E5 N 
Methamphetamine 150.1 2.6E5 ND 1.9E5 2.25E5 3.63E5 N 
MDMA 194.1 ND 1.2E5 1.3E5 1.25E5 1.18E5 P 
MDA 180.0 ND 1.6E5 2.0E5 1.80E5 2.38E5 N 
MDMA/MDA 163.1 1.9E5 2.1E5 2.6E5 2.2E5 2.63E5  
Cocaine 304.2 ND ND 2.2E5 - 2.1E5 N 
Benzoylecgonine 290.0 2.2E5 1.7E5 1.8E5 1.9E5 2.41E5 N 168.1 2.0E5 1.4E5 1.9E5 1.77E5 1.65E5 
ND-not detected; N-negative; P-positive. 
Table 16. Results obtained for Case 5. 




Spot 3 Average 
Cut-off 
intensity Result 
Morphine 286.1 9.8E5 1.1E6 9.7E5 1.02E6 1.75E6 N 
6-monoacetylmorphine 328.2 ND ND ND - 2.33E5 N 
Oxycodone 316.1 ND ND ND - 2.20E5 N 
Hydrocodone/Codeine 300.2 ND ND ND - 2.19E5 N 
Fentanyl 337.3 ND ND ND - 6.92E5 N 
Norfentanyl 233.1 1.3E5 1.7E5 ND 1.63E5 2.84E5 N 
Methadone 310.2 2.8E6 2.9E6 2.9E6 2.87E5 2.03E6 P 265.0 2.6E6 2.7E6 3.0E6 2.77E6 1.32E6 
EDDP 278.1 3.1E6 3.2E6 3.9E6 3.4E6 1.52E6 P 
Amphetamine 136.1 3.7E5 3.5E5 2.4E5 3.3E5 3.68E5 N 
Methamphetamine 150.1 2.6E5 3.0E5 1.7E5 2.43E5 3.63E5 N 
MDMA 194.1 ND ND ND - 1.18E5 N 
MDA 180.0 ND 1.9E5 ND - 2.38E5 N 
MDMA/MDA 163.1 1.9E5 1.8E5 2.1E5 1.93E5 2.63E5  
Cocaine 304.2 ND ND ND - 2.10E5 N 
Benzoylecgonine 290.0 2.2E5 2.0E5 2.1E5 2.1E5 2.41E5 N 168.1 2.0E5 1.8E5 2.0E5 1.93E5 1.65E5 






 After employing the screening assay to test case samples 1 through 5, EMIT was 
performed on each sample (Table 17), and the results of the immunoassay screen were 
compared to the results of the DUS screen we developed, and to the actual results (Table 
18). 
Table 17. Results of EMIT screening of cases 1-5 
EMIT ASSAY Results 
 Case 1 Case 2 Case 3 Case 4 Case 5 
Amphetamines N N N N N 
Cocaine N N P P N 
Methadone N N N N P 
Opiates N P N N N 
 
Table 18. Summary of screening results compared to actual drug composition of sample. 
Amphetamine (A); methamphetamine (MA); benzoylecgonine (BE); hydrocodone (HC); 
oxycodone (OC). 
Case DUS screen results EMIT Results Actual 
1 
Positive for A 
Positive for MA 
Positive for BE 
Negative for all tests Positive for A Positive for MA 
2 Negative for all analytes Positive for opiates Positive for morphine Positive for HC 
3 Negative for all analytes Positive for cocaine Positive for BE 
4 Positive for MDMA Positive for cocaine Positive for BE Positive for MDMA 
5 Positive for methadone Positive for EDDP Positive for methadone 
Positive for methadone 
Positive for EDDP 
Positive for OC 
 
 Regarding our DUS screening method, Case 1 was actually positive for 






methamphetamine were true positives but the detection of benzoylecgonine was a false 
positive. The Case 2 sample contained morphine and hydrocodone at 500 ng/mL. Five-
hundred ng/mL is below the LOD for hydrocodone in our method, so it was not detected 
and, as described earlier, the endogenous interference(s) at 286 m/z complicate the 
interpretation of results for morphine. The Case 3 sample contained benzoylecgonine at 
500 ng/mL. However, the peak intensities for both of the ions of interest, while close to 
the cut-off, were below the cut-off intensity and a determination of negative was made. 
The Case 4 sample contained benzoylecgonine and MDMA at 500 ng/mL. The results 
indicated a positive result for MDMA but the peak intensities for the benzoylecgonine 
peaks were below the cut-off, so it was designated as negative for that substance. The 
Case 5 sample contained 500 ng/mL of methadone, EDDP, and oxycodone. The results of 
the screening method indicated a positive result for methadone and EDDP, but were 
negative for oxycodone. Five-hundred ng/mL is below the LOD for oxycodone in 
authentic urine for this method, and therefore, it was not detected. Overall, the DUS 
screening method developed resulted in 5 true positives, 59 true negatives, 1 false 
positive, and 5 false negatives. 
 Regarding the EMIT screening results, for the case 1 sample, the EMIT results 
indicated that the sample was negative for amphetamines, cocaine, methadone and 
opiates, even though actually contained both amphetamine and methamphetamine. This 
false negative is due to the concentration of the analytes. The amphetamines EMIT screen 
was performed at cut-off concentration of 1,000 ng/mL, which is based on the signal 
produced by a 1,000 ng/mL d,l-amphetamine calibrator. Amphetamine and 






concentration and therefore were not detected. The EMIT results for Case 2 showed that 
the sample was positive for opiates and the sample did contain morphine and 
hydrocodone. Using a cut-off concentration of 300 ng/mL, morphine will be detected by 
the opiate EMIT screen at a concentration of 300 ng/mL (morphine is used as the 
calibrator) and hydrocodone will be detected at a concentration of 247 ng/mL (Siemens, 
2017). This result is a true positive. However, the EMIT opiate assay is not specific 
enough to indicate which opiates are actually present in the sample. For Case 3, the 
EMIT results indicated that the sample was positive for cocaine. The assay actually 
detects the presence of the cocaine metabolite, benzoylecgonine, which was present. 
Therefore, this result was a true positive. For Case 4, the EMIT results indicated that the 
sample was positive for cocaine metabolite. However, it was unable to detect MDMA. 
According to Siemens (2017), MDMA will produce a positive result in the amphetamine 
assay at a concentration of 34,300 ng/mL when using a cut-off concentration of 1,000 
ng/mL. The extremely high concentration of MDMA required to produce a positive 
signal resulted in a false negative. For Case 5, the EMIT results indicated that the sample 
was positive for methadone, which was accurate. However, the EMIT methadone assay is 
specific for methadone only, thus, EDDP was not detected. The results showed that the 
sample was negative for opiates as well, despite the presence of oxycodone. At a cut-off 
concentration of 300 ng/mL, oxycodone will be detected in the opiate screen at a 
concentration of 1,500 ng/mL. Since the concentration of oxycodone in the Case 5 
sample was 500 ng/mL, it was not detected, and this resulted in a false negative. Overall, 
the EMIT screening method resulted in 4 true positives, 13 true negatives, 0 false 






 When comparing the results of our DUS screening method to the results of the 
EMIT assays, the advantages and drawbacks of each method are highlighted. In general, 
our DUS screening method is more specific than the EMIT assays. Among the four 
EMIT assays we used, only the methadone and cocaine metabolite assays are specific for 
a particular analyte. The opiate assay can produce a positive result for numerous natural 
and semi-synthetic opioids. However, as seen with oxycodone, they do not all produce a 
positive result at the cut-off concentration. According to Siemens’ cross-reactivity data 
(2017), when using the 300 ng/mL cut-off level, 6-AM, codeine, hydrocodone, and 
oxycodone will give an assay response equal to the morphine cut-off calibrator at a 
concentration of 435, 102-306, 247, and 1,500 ng/mL, respectively. Thus, the opiate 
assay is not equally sensitive for all opiates. Furthermore, the opiate assay does display 
cross reactivity with some non-opiate drugs such as the antibiotics ofloxacin and 
levofloxacin and the emergency opiate antagonist naloxone. In contrast, the DUS method 
that we developed can distinguish between the different opiates, with the exception of 
isobaric compounds such as hydrocodone and codeine. Also, EMIT is more sensitive for 
morphine, 6-AM, codeine and hydrocodone but our method is more sensitive for 
oxycodone. Another disadvantage of the EMIT opiate assay is that it does not detect 
synthetic opiates and their metabolites such as fentanyl, norfentanyl, methadone, and 
EDDP, which are compounds that our DUS method is highly sensitive for. 
 When comparing the DUS method with EMIT screening for amphetamines, our 
method appears to be superior at the 1,000 ng/mL EMIT cut-off level. First, our DUS 
method is more sensitive for amphetamine, methamphetamine, MDA, and MDMA than 






ng/mL using the DUS method. For the EMIT amphetamine assay, methamphetamine, 
MDA, and MDMA give an assay response equal to the 1,000 ng/mL amphetamine cut-
off calibrator at 2100, 6500, and 34,300 ng/mL, respectively (Siemens, 2017). Just as 
with the opiate assay, the EMIT amphetamine assay is not equally sensitive for all of the 
amphetamines and very high urine concentrations are required to produce a signal above 
the cut-off level for MDA and MDMA. In addition, the amphetamine assay also displays 
cross-reactivity with substances that are not amphetamines such as the antidepressant 
bupropion, the anti-malarial drugs chloroquine and quinacrine, the Alzheimer’s drug 
donepezil, the heart medication mexiletine, the beta-blocker propranolol, and the MAO-B 
inhibitor selegiline (Siemens, 2017). The greater sensitivity and specificity for the 
amphetamine drugs tested in the developed DUS screening method appear to indicate that 
our method is superior for the detection of amphetamines compared to the EMIT assay.  
 Based on the failure to accurately detect and identify benzoylecgonine in the DUS 
samples using the developed screening method, the EMIT cocaine metabolite assay 
appears to be the superior method to screen for cocaine use. When analyzing the 
unfortified authentic urine samples, possible interferences were detected for the 
benzoylecgonine ions of interest more often than not. Despite being able to accurately 
detect cocaine with our method, it is too unreliable to make determinations about the 
presence of benzoylecgonine in urine. In addition, the EMIT cocaine assay also provides 
an assay response equal to the 300 ng/mL benzoylecgonine calibrator for cocaine at 40-
119 ng/mL and ecgonine at 7-20 ng/mL. No other compounds were reported to display 






assay is more reliable for the detection of benzoylecgonine and more sensitive for 
cocaine as compared to our DUS method.  
 Finally, our DUS screening method appears to be superior to the EMIT 
methadone assay. The EMIT methadone assay is specific to methadone only and does not 
detect the metabolite EDDP. Our screening method was consistently able to detect 
methadone and EDDP in the fortified authentic urine and case 5 samples. The ability to 
detect both methadone and EDDP in urine may be useful for certain applications such as 
monitoring methadone compliance (George & Braithwaite, 1999). In addition, our DUS 
screening method is more sensitive for methadone than the EMIT assay. The LOD for 
methadone and EDDP for the DUS screening method was determined to be 100 ng/mL 
while the cut-off level for EMIT methadone assay is 300 ng/mL. The higher sensitivity 
and ability to detect EDDP in addition to methadone are advantageous features of our 
DUS screening method as compared to traditional EMIT screening.  
 While both our DUS method and EMIT screening have their advantages and 
disadvantages, our method has the major advantage of easily incorporating new analytes 
into the assay. EMIT and other immunoassays rely on antibody-antigen interactions 
(Hoofnagle & Wener, 2009). Therefore, development a new EMIT assay requires the 
development of new antibodies specific for a particular drug or drug class. This is 
difficult, costly, and extremely time consuming (Hoofnagle & Wener, 2009). Therefore, 
mass spectrometry based screening methods, such as the screening method presented 
here, may offer a solution to the problems associated with immunoassay screening 







 Drug screening is an essential part of toxicological analysis, but it can be time 
consuming and costly. Direct sampling of dried matrix spots and analysis by mass 
spectrometry provides an alternative method for drug screening that is simple, fast, and 
cost effective. We developed a method for the direct analysis of DUS samples using a 
TLC-CMS interface for opioids, amphetamines and cocaine screening. While the DUS 
method developed and described in this work does have potential, it also has 
shortcomings. When using the TLC-CMS interface no chromatography is used so all 
compounds are subjected to mass spectrometric analysis simultaneously. This problem is 
exacerbated by direct analysis because urinary matrix components are also present in the 
sample. The inability to distinguish analytes of interest from urinary matrix components 
can lead to false positives, especially at lower concentrations. However, it does have 
certain advantages over traditional immunoassay screening methods such as EMIT 
because it has the potential to give more specific results rather than giving a result for a 
broad group of drugs, such as opioids. In addition, new drugs and metabolites can easily 
be added to our method and validated. It is difficult and time consuming to develop a new 
immunoassay and validate it because these tests rely on the development of specific 
antibodies to bind each drug. This makes our DUS superior for screening for drugs like 
fentanyl and its metabolite norfentanyl, for which there is no commercially available 
EMIT assay kit.  
 The sensitivity and specificity of the DUS method presented could be improved 
by introducing a sample pre-treatment step, chromatographic separation, or employing a 






preparation and analysis time and high-resolution mass spectrometers are much larger 
than the CMS system used in this work. Since the method described in this work is a 
screening method, all results need to be followed by a confirmatory analysis by GC-MS 
or LC-MS/MS so further investigation and optimization of instrumental parameters 
should be conducted in order to decrease the rate of false positives and negatives. Despite 
these shortcomings, direct sampling of DMS coupled to mass spectrometry has great 
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Figure A1. Mass spectrum of 6-monoacetylmorphine in methanol at 100 ng/mL. 
 
 
Figure A2. Mass spectrum of 6-monoacetylmorphine in synthetic urine at 250 ng/mL. 
 
Figure A3. Mass spectrum of 6-monoacetylmorphine in authentic urine at 500 ng/mL. 
 





 c/s  
0.00 0.33 0.67 1.00 1.33 1.67 2.00 2.33
Min
TIC Filtered 






 %  
100 200 300 400 500
m/z
Spectrum RT 0.00 - 2.61 {317 scans} 
2019_3_20_6MAM0.25 2019.03.20 14:23:48 6 MAM (0.25 ug/mL) on DBS card;









 c/s  
0.00 0.17 0.33 0.50 0.67 0.83
Min
TIC Filtered 






 c/s  
0.00 0.17 0.33 0.50 0.67 0.83
Min
TIC Filtered 







 %  
315 320 325 330 335 340
m/z
Spectrum RT 0.00 - 0.94 {65 scans} 
6-MAM 0.5_Scan1 2019.04.05 12:15:43 scan MeOH;








 %  
327.4 327.6 327.8 328 328.2 328.4 328.6 328.8
m/z
Spectrum RT 0.01 - 0.96 {66 scans} 
6-MAM 0.5_SIM2 2019.04.05 12:15:43 scan MeOH;





 c/s  
0.00 0.33 0.67 1.00 1.33 1.67 2.00
Min
TIC Filtered 







 c/s  
0.00 0.33 0.67 1.00 1.33 1.67 2.00
Min
TIC Filtered 
04162019_6-MAM 10-2_SIM2 2019.04.16 10:42:50 6-MAM (10 ug/mL) authentic urine;
ESI +
99.0%; 328.1




 %  
315 320 325 330 335
m/z
Spectrum RT 0.00 - 2.16 {174 scans} 
04162019_6-MAM 10-2_Scan1 2019.04.16 10:42:50 6-MAM (10 ug/mL) authentic urine;







 %  
310 320 330 340 350 360 370 380
m/z
Spectrum RT 0.01 - 2.18 {175 scans} 
04162019_6-MAM 10-2_SIM2 2019.04.16 10:42:50 6-MAM (10 ug/mL) authentic urine;







.00 0.33 0.67 1.00 1.33 1.67 2.00
Min
ΔIC Filtered 
2019_3_11_amp_neat 2019.03.11 13:27:31 Neat amp on DBS card;
ESI +




 %  
50 100 150 200 250 300 350 400 450
m/z
ΔS 1.47 - 1.60 {16 scans} 
2019_3_11_amp_neat 2019.03.11 13:27:31 Neat amp on DBS c rd;
ESI + Max: .3E2
91.0
132.0







Figure A5. Mass spectrum of amphetamine in synthetic urine at 250 ng/mL. 
 
Figure A6. Mass spectrum of amphetamine in authentic urine at 500 ng/mL. 
 
Figure A7. Mass spectrum of benzoylecgonine in methanol at 100 ng/mL. 
 
Figure A8. Mass spectrum of benzoylecgonine in synthetic urine at 100 ng/mL. 
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Figure A9. Mass spectrum of benzoylecgonine in authentic urine at 200 ng/mL. 
 
Figure A10. Mass spectrum of cocaine in methanol at 100 ng/mL. 
 
Figure A11. Mass spectrum of cocaine in synthetic urine at 100 ng/mL. 
 
Figure A12. Mass spectrum of cocaine in authentic urine at 200 ng/mL. 
 




 c/s  
0.00 0.08 0.17 0.25 0.33 0.42 0.50 0.58 0.67 0.75
Min
TIC Filtered 







 %  
285 290 295 300
m/z
Spectrum RT 0.00 - 0.78 {102 scans} 
0506_BE 10-3 2019.05.07 12:12:08 authentic urine 3;








 c/s  
0.00 0.17 0.33 0.50 0.67 0.83 1.00 1.17 1.33
Min
TIC Filtered 
2019_3_11_cocaine_neat 2019.03.11 13:13:25 Neat cocaine on DBS card;
ESI +
98.5%; 304.1




 %  
100 150 200 250 300 350 400 450
m/z
Spectrum RT 0.00 - 1.41 {172 scans} 
2019_3_11_cocaine_neat 2019.03.11 13:13:25 Neat cocaine on DBS card;




144.9 183.1154.9 180.9146.9 196.0 272.1
2E9
Intensity
 c/s  
0.00 0.17 0.33 0.50 0.67 0.83
Min
TIC Filtered 






 %  
296 298 300 302 304 306 308
m/z
Spectrum RT 0.00 - 0.82 {103 scans} 
syn urine cocaine 2019.07.03 11:45:45 syn urine;








 c/s  
0.00 0.17 0.33 0.50 0.67 0.83 1.00 1.17 1.33 1.50
Min
TIC Filtered 





 %  
275 280 285 290 295 300 305 310 315 320
m/z
Spectrum RT 0.00 - 1.59 {207 scans} 
0430_cocaine 1 2019.04.30 13:04:11 blank syn urine;




287.0275.1 289.0 312.2284.2 299.1
1E9
Intensity
 c/s  
0.00 0.17 0.33 0.50 0.67 0.83 .00 1.17
Min
TIC Filtered 








 %  
100 150 200 250 300 350 400 450
m/z
Spectrum RT 0.00 - 1.25 {152 scans} 
2019_3_25_codeine_10 2019.03.25 11:40:44 codeine std (10 ug/mL) on DBS card;











Figure A14. Mass spectrum of codeine in synthetic urine at 500 ng/mL. 
 
Figure A15. Mass spectrum of codeine in authentic urine at 1000 ng/mL. 
 
Figure A16. Mass spectrum of EDDP in methanol at 100 ng/mL. 
 
Figure A17. Mass spectrum of EDDP in synthetic urine at 100 ng/mL. 
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Figure A19. Mass spectrum of fentanyl in methanol at 100 ng/mL. 
 
Figure A20. Mass spectrum of fentanyl in synthetic urine at 100 ng/mL. 
 
Figure A21. Mass spectrum of fentanyl in authentic urine at 100 ng/mL. 
 
Figure A22. Mass spectrum of hydrocodone in methanol at 500 ng/mL. 
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Figure A24. Mass spectrum of hydrocodone in authentic urine at 1000 ng/mL. 
 
Figure A25. Mass spectrum of MDA in methanol at 100 ng/mL. Spectrum is zoomed in 
to show 180.0 m/z peak. 
 
Figure A26. Mass spectrum of MDA in methanol at 100 ng/mL. Spectrum is zoomed in 
to show 163.0 m/z peak. 
 
 
Figure A27. Mass spectrum of MDA in synthetic urine at 250 ng/mL. Spectrum is 
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Figure A28. Mass spectrum of MDA in synthetic urine at 250 ng/mL. Spectrum is 
zoomed in to show 163.0 m/z peak. 
 
 
Figure A29. Mass spectrum of MDA in authentic urine at 500 ng/mL. Spectrum is 
zoomed in to show 180.0 m/z peak. 
 
 
Figure A30. Mass spectrum of MDA in authentic urine at 500 ng/mL. Spectrum is 
zoomed in to show 163.1 m/z peak. 
 
 
Figure A31. Mass spectrum of MDMA in methanol at 100 ng/mL. 
 
 
Figure A32. Mass spectrum of MDMA in synthetic urine at 250 ng/mL. Spectrum is 
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Figure A33. Mass spectrum of MDMA in synthetic urine at 250 ng/mL. Spectrum is 
zoomed in to show 163.0 m/z peak. 
 
 
Figure A34. Mass spectrum of MDMA in authentic urine at 500 ng/mL. Spectrum is 
zoomed in to show 194.1 m/z peak. 
 
 
Figure A35. Mass spectrum of MDMA in authentic urine at 500 ng/mL. Spectrum is 
zoomed in to show 163.1 m/z peak. 
 
 
Figure A36. Mass spectrum of methamphetamine in methanol at 100 ng/mL.  
 
 
Figure A37. Mass spectrum of methamphetamine in synthetic urine at 250 ng/mL. 
Spectrum is zoomed in to show 150.1 m/z peak. 
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Figure A38. Mass spectrum of methamphetamine in synthetic urine at 250 ng/mL. 
Spectrum is zoomed in to show 119.1 m/z peak. 
 
 
Figure A39. Mass spectrum of methamphetamine in synthetic urine at 250 ng/mL. 
Spectrum is zoomed in to show 91.1 m/z peak. 
 
 
Figure A40. Mass spectrum of methamphetamine in authentic urine at 500 ng/mL. 
 
 
Figure A41. Mass spectrum of methadone in methanol at 100 ng/mL. 
 
 
Figure A42. Mass spectrum of methadone in synthetic urine at 100 ng/mL. Spectrum is 
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Figure A43. Mass spectrum of methadone in synthetic urine at 100 ng/mL. Spectrum is 
zoomed in to show 265.0 m/z peak. 
 
 
Figure A44. Mass spectrum of methadone in authentic urine at 100 ng/mL. 
 
 
Figure A45. Mass spectrum of morphine in methanol at 100 ng/mL. 
 
 
Figure A46. Mass spectrum of morphine in synthetic urine at 250 ng/mL. 
 
 




 c/s  
0.00 0.17 0.33 0.50 0.67 0.83 1.00 1.17 1.33
Min
TIC Filtered 







 %  
255 260 265 270 275
m/z
Spectrum RT 0.00 - 1.45 {190 scans} 
0430_methadone 0.1 2019.04.30 12:01:52 blank syn urine;











 c/s  
0.00 0.33 0.67 1.00 1.33 1.67
Min
TIC Filtered 







 %  
260 270 280 290 300 310 320 330
m/z
Spectrum RT 0.00 - 1.76 {230 scans} 
0503-methadone 0.1-1 2019.05.03 11:10:49 authentic urine 1;












 c/s  
0.00 0.33 0.67 1.00 1.33 1.67 2.00 2.33 2.67 3.00
Min
TIC Filtered 









 c/s  
100 200 300 400 500
m/z
Spectrum RT 0.00 - 3.03 {367 scans} 









 c/s  
0.00 0.17 0.33 0.50 0.67 0.83 1.00 1.17
Min
Chromatogram TIC Filtered 






 %  
150 200 250 300 350 400
m/z
Spectrum RT 0.00 - 1.29 {161 scans} 
syn urine morphine 2019.07.03 11:54:59 syn urine;









 c/s  
0.00 0.17 0.33 0.50 0.67 0.83 1.00 1.17 1.33 1.50
Min
TIC Filtered 






 %  
150 200 250 300 350 400 450
m/z
Spectrum RT 0.00 - 1.62 {210 scans} 
0506_morphine 0.25-4 2019.05.07 12:43:51 authentic urine 3;













Figure A48. Mass spectrum of norfentanyl in methanol at 100 ng/mL. 
 
 
Figure A49. Mass spectrum of norfentanyl in synthetic urine at 100 ng/mL. 
 
 
Figure A50. Mass spectrum of norfentanyl in authentic urine at 100 ng/mL. 
 
 
Figure A51. Mass spectrum of oxycodone in methanol at 500 ng/mL. 
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